# US 2018/0021358 A1 · Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021358 A1
- Document ID: US20180021358A1
- Status: Published application
- Kind: A1
- Application number: 15/697,267
- Filed: 2017-09-06
- Published: 2018-01-25
- Earliest claimed: 2012-05-14
- Assignees: Antecip Bioventures II LLC
- Applicants: Antecip Bioventures II LLC
- Inventors: Herriot Tabuteau
- Web page: https://patentgrep.com/patent/US20180021358A1

## CPC

- A61K 31/663: Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/2004: {Excipients; Inactive ingredients}
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.

## Claims

### Claim 1

A method of treating pain associated with complex regional pain syndrome comprising orally administering a dosage form comprising zoledronic acid to a human being suffering from complex regional pain syndrome incited by a fracture;
wherein the dosage form is administered 2, 3, or 4 times within a period of about one month so that a total of about 200 mg/m2 to about 400 mg/m2 of the zoledronic acid is administered to the human being;
wherein an AUC of zoledronic acid in the human being, measured over a period of one month from the first time the dosage form is orally administered, is about 500 ng·h/mL to about 1000 ng·h/mL;
wherein the dosage form provides a bioavailability of zoledronic acid of about 1.1% to about 1.8% to the human being;
wherein the human being fasts for at least one hour before the zoledronic acid is orally administered and for at least one hour after the zoledronic acid is orally administered; and
wherein the human being remains upright for at least about 30 minutes after the zoledronic acid is orally administered.

### Claim 2 (depends on 1)

The method of claim 1, wherein the zoledronic acid is in an acid form.

### Claim 3 (depends on 1)

The method of claim 1, wherein the zoledronic acid is in a salt form.

### Claim 4 (depends on 3)

The method of claim 3, wherein the zoledronic acid is in a disodium salt form.

### Claim 5 (depends on 1)

The method of claim 1, wherein the zoledronic acid is orally administered in at least two consecutive doses that are at least about 1 week apart.

### Claim 6 (depends on 1)

The method of claim 1, wherein the total of about 200 mg/m2 to about 400 mg/m2 of the zoledronic acid is orally administered for only 1 month.

### Claim 7 (depends on 1)

The method of claim 1, wherein the total amount of about 400 mg/m2 to about 800 mg/m2 of the zoledronic acid is orally administered within 2 months.

### Claim 8 (depends on 1)

The method of claim 1, wherein the AUC of zoledronic acid in the human being, measured over a period of one month, is about 500 ng·h/mL to about 700 ng·h/mL.

### Claim 9 (depends on 1)

The method of claim 1, wherein the AUC of zoledronic acid in the human being, measured over a period of one month, is about 700 ng·h/mL to about 1000 ng·h/mL.

### Claim 10 (depends on 1)

The method of claim 1, wherein the zoledronic acid is in a dosage form that provides a bioavailability of zoledronic acid of about 1.1% to about 1.5% when orally administered to the human being in a fasted state.

### Claim 11

A method of treating pain associated with complex regional pain syndrome comprising orally administering a dosage form to a human being suffering from complex regional pain syndrome incited by a fracture;
wherein the dosage form is prepared by a method comprising combining 1) about 40 mg to about 200 mg of zoledronic acid with 2) an excipient, a disintegrating agent, a diluent, a binder, a lubricant, a flavoring agent, a coating, a capsule, or a combination thereof;
wherein the dosage form is orally administered 2 to 9 times at an interval that is at least about once weekly; and
wherein, beginning when the dosage form is first orally administered, an AUC of zoledronic acid in the human being, measured over a period of one month, is about 500 ng·h/mL to about 1000 ng·h/mL;
wherein the dosage form provides a bioavailability of zoledronic acid of about 1% to about 3% to the human being;
wherein the human being fasts for at least about two hours before the zoledronic acid is orally administered and for at least one hour after the zoledronic acid is orally administered; and
wherein the human being remains upright for at least about one hour after the zoledronic acid is orally administered.

### Claim 12 (depends on 11)

The method of claim 11, wherein the zoledronic acid is in an acid form.

### Claim 13 (depends on 11)

The method of claim 11, wherein the zoledronic acid is in a salt form.

### Claim 14 (depends on 13)

The method of claim 13, wherein the zoledronic acid is in a disodium salt form.

### Claim 15 (depends on 11)

The method of claim 11, wherein the bioavailability of zoledronic acid in the dosage form is about 1% to about 1.3%, as determined when orally administered to a human being who has fasted for eight hours.

### Claim 16 (depends on 11)

The method of claim 11, wherein the bioavailability of zoledronic acid in the dosage form is about 1.2% to about 1.5%, as determined when orally administered to a human being who has fasted for eight hours.

### Claim 17 (depends on 11)

The method of claim 11, wherein the bioavailability of zoledronic acid in the dosage form is about 1.5% to about 2%, as determined when orally administered to a human being who has fasted for eight hours.

### Claim 18 (depends on 11)

The method of claim 11, wherein the bioavailability of zoledronic acid in the dosage form is about 2% to about 3%, as determined when orally administered to a human being who has fasted for eight hours.

### Claim 19 (depends on 11)

The method of claim 11, wherein the dosage form contains about 150 mg to about 200 mg of the zoledronic acid, based upon the weight of the zoledronic acid in a diacid form.

### Claim 20 (depends on 14)

The method of claim 14, wherein the dosage form contains about 50 mg to about 60 mg of the disodium salt form of the zoledronic acid.

### Claim 21 (depends on 11)

The method of claim 11, wherein the dosage form contains about 50 mg of the zoledronic acid, based upon the weight of the zoledronic acid in a diacid form.

### Claim 22 (depends on 11)

The method of claim 11, wherein the human being has an average weekly pain intensity of at least 4, on the 0-10 numeric rating scale, prior to receiving the zoledronic acid.

### Claim 23 (depends on 11)

The method of claim 11, wherein the human being has an average weekly pain intensity of at least 5, on the 0-10 numeric rating scale, prior to receiving the zoledronic acid.

### Claim 24 (depends on 11)

The method of claim 11, wherein the human being is at least 18 years of age.

### Claim 25

A method of treating pain associated with complex regional pain syndrome comprising orally administering a dosage form comprising zoledronic acid in an acid form or a salt form to a human being suffering from complex regional pain syndrome precipitated by a fracture;
wherein an AUC of zoledronic acid in the human being, measured over a period of one month, is about 500 ng·h/mL to about 1000 ng·h/mL;
wherein the bioavailability of zoledronic acid in the dosage form is about 1.1% to about 1.5%, as determined when orally administered to a human being who has fasted for eight hours;
wherein the human being has an average weekly pain intensity of at least 4, on the 0-10 numeric rating scale, prior to receiving the zoledronic acid;
wherein the human being fasts for at least 30 minutes before the zoledronic acid is orally administered and for at least 30 minutes after the zoledronic acid is orally administered; and
wherein the human being remains upright for at least about 30 minutes after the zoledronic acid is orally administered.

### Claim 26 (depends on 25)

The method of claim 25, wherein a single oral administration of the dosage form results in an AUC of zoledronic acid of about 200 ng·h/mL to about 400 ng·h/mL.

### Claim 27 (depends on 25)

The method of claim 25, wherein the dosage form is orally administered three times.

### Claim 28 (depends on 25)

The method of claim 25, wherein an amount of an opioid that is orally administered to the human being is reduced after the dosage form is orally administered.

### Claim 29 (depends on 25)

The method of claim 25, wherein the human being has an average weekly pain intensity of at least 6, on the 0-10 numeric rating scale, prior to receiving the zoledronic acid.

### Claim 30 (depends on 25)

The method of claim 25, wherein the human being has an average weekly pain intensity of at least 7, on the 0-10 numeric rating scale, prior to receiving the zoledronic acid.
